SAN DIEGO, CA — May 6, 2026 — Leads & Copy —
Simulations Plus, Inc. (Nasdaq: SLP) has launched a technical collaboration with NVIDIA to enable GPU-accelerated simulation and AI-assisted workflows for computationally intensive modeling applications within the drug development lifecycle.
The collaboration combines Simulations Plus’ scientific engines across physiologically-based pharmacokinetics (PBPK), pharmacokinetics/pharmacodynamics (PK/PD), and quantitative systems pharmacology (QSP) with NVIDIA AI infrastructure. The goal is to accelerate and scale simulation cycles, parameter exploration, and virtual population studies.
These capabilities address two constraints in model-informed drug development (MIDD): reducing manual, expertise-driven work and enabling large-scale exploration of model structures and parameters. This aims to shift modeling from a sequential process to a more iterative, data-informed workflow operating at program-relevant timelines.
NVIDIA is contributing advanced computing infrastructure and expertise in accelerated inference and GPU-native optimization to improve simulation performance and enable interactive, AI-assisted workflows. NVIDIA also provides access to its life sciences ecosystem, including the NVIDIA BioNeMo platform and a global network of pharmaceutical partners.
According to Shawn O’Connor, Chief Executive Officer of Simulations Plus, the collaboration brings together validated science, accelerated computing, and AI capabilities to expand what scientific teams can explore and accomplish.
The collaboration is initially focused on three areas:
Simulations Plus has begun developing GPU-optimized simulation capabilities for QSP and PK/PD applications, reducing runtimes and enabling broader exploration of complex biological systems. This enables scientists to evaluate a broader range of hypotheses without pre-pruning models, increasing confidence in model selection and supporting more robust program decisions.
Simulations Plus is applying AI-assisted approaches, informed by NVIDIA’s expertise in accelerated inference and agentic AI, to support model construction, parameter fitting, diagnostics, and refinement. This aims to reduce manual effort and accelerate iteration from question to analysis. These workflows will allow scientists to focus more on scientific interpretation and decision-making, accelerating iteration cycles within drug development programs.
Simulations Plus is prioritizing QSP workflows by applying GPU acceleration and AI-assisted methods to improve simulation efficiency and expand practical use in pharmaceutical R&D. Current testing shows up to a 75% reduction in time required for end-to-end QSP modeling, enabling faster iteration and expanding the practical use of QSP within program timelines.
As part of the collaboration, the companies plan to engage select pharmaceutical partners to evaluate these capabilities in real-world drug development workflows, with an initial focus on high-complexity modeling use cases.
Erik Guffrey, Co-Chief Product and Technology Officer of Simulations Plus, said that scientific teams are seeking faster iteration, greater scale, and better ways to work across increasingly complex modeling problems. By combining validated scientific engines with AI-assisted workflows and accelerated computing, Simulations Plus is extending its platform into a more integrated modeling ecosystem.
Anthony Costa, Director of Digital Biology and Health, NVIDIA, said that biopharma teams need platforms that can connect mechanistic modeling, AI, and high-performance simulation into workflows scientists can use. NVIDIA believes that by bringing its accelerated computing and AI infrastructure together with Simulations Plus’ expertise in model-informed drug development, researchers can run more complex models, explore larger design spaces, and move from insight to decision faster.
Simulations Plus is a global leader in model-informed and AI-accelerated drug development, creating value for clients by accelerating the discovery, development, and commercialization of pharmaceuticals and other products through science-based software and consulting solutions.
Source: Simulations Plus
